At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
nemolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis
In Brief
A Phase 2 clinical trial evaluating nemolizumab for Systemic Sclerosis. Completed, enrolled 6 participants across 1 site.
Detailed Summary
To evaluate the efficacy of nemolizumab in systemic sclerosis patients. To evaluate also the safety and pharmacokinetics.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Sclerosis
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedJan 2022
Enrollment StartApr 2022
Primary CompletionJun 2024
Study CompletionJul 2024
TodayJul 2026
First PostedJan 31, 2022
Enrollment StartApr 20, 2022
Primary CompletionJun 4, 2024
Study CompletionJul 30, 2024
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 4.4 years ago
Interventions
nemolizumabdrug
nemolizumab will be administered subcutaneous injection